Terumo launches SurTract retractable syringe in US

USA—Terumo Medical has introduced its SurTract Safety Syringe to the United States healthcare market, marking a significant advancement in medical injection safety.

The company incorporates Roncadelle Operations’ SafeR passive safety technology into this new product, bringing enhanced protection features to healthcare professionals across the country.

Healthcare facilities throughout the United States will begin receiving the SurTract Safety Syringe starting in the first quarter of this year.

Terumo plans to distribute the product to hospitals, clinics, and emergency care settings nationwide, making the technology widely accessible to medical professionals who perform injections daily.

The SafeR technology represents the core innovation behind the SurTract Safety Syringe’s protective capabilities.

This system equips the syringe with a fully passive, automatic retraction mechanism that activates immediately after use.

 Healthcare workers do not need to manually engage any safety features, as the needle withdraws into the plunger automatically once the injection is complete.

This immediate retraction significantly reduces the risk of accidental needle-stick injuries, which pose serious health hazards to medical personnel.

Medical professionals can continue using their standard clinical techniques while benefiting from the enhanced safety features.

The automatic retraction mechanism operates seamlessly without requiring changes to established injection procedures, allowing healthcare workers to maintain their familiar workflows while enjoying improved protection.

This design approach ensures that safety enhancements do not compromise efficiency or add complexity to routine medical tasks.

Terumo offers customizable needle options specifically designed for use with SurTract Syringes, giving physicians the flexibility to select combinations that best suit individual patient requirements.

This customization capability allows medical professionals to optimize their treatment approach based on specific clinical scenarios and patient characteristics.

The syringe also features a blunt needle option that addresses common practical challenges during medical procedures.

This alternative prevents the needle from becoming dull during use and enables healthcare workers to replace needles during aspiration procedures when necessary.

These features contribute to better clinical outcomes and improved procedural flexibility.

Environmental considerations influenced the design of the SurTract Safety Syringe as well.

The product eliminates the need for an external plastic safety sheath, thereby reducing medical waste generated during routine injections.

This streamlined design delivers both safety benefits and environmental advantages.

Bob Klock, vice president at Terumo, emphasized the collaboration’s value in bringing this product to market.

He explained that the SurTract Syringe merges Terumo’s established clinical expertise with Roncadelle’s proven SafeR technology to create a straightforward yet effective solution for safer injections.

Klock stated that providing healthcare providers with superior treatment options for their patients remains the company’s primary objective.

Dr. Fred Metzmann, chief business development officer at Roncadelle Operations, highlighted how Terumo has substantially advanced injection safety through the integration of SafeR technology.

He described the partnership as delivering a next-generation syringe system that combines intuitive operation, reliable performance, and engineering designed specifically to protect healthcare professionals.

Roncadelle’s SafeR product portfolio extends beyond this single product, encompassing various needle-guard systems and passive safety syringes developed for safe injection practices and protection within clinical environments.

In October 2025, Terumo completed its acquisition of OrganOx for approximately USD1.5 billion after satisfying all required regulatory approvals and closing conditions.